Lenvatinib Plus Pembrolizumab

12 Mar, 2021

Dr. Rajesh Bollam

Image

Lenvatinib plus pembrolizumab🧪associated w/ significantly longer progression-free survival and overall survival than sunitinib in Advanced Renal Cell Carcinoma‼️#KidneyCancer #RCC

⚡️⚡️ History in the making!

👏Lenvatinib+pembro vs Sun

✅PFS 20.9 mos vs 9.2 mos HR 0.39 p<0.001

✅OS HR:0.66 p=0.005

✅ORR 71% vs 36%, CR16%vs4%

👏Len+Eve vs Sun

✅PFS14.7 vs 9.2 mos HR0.65 p<0.001

#DrRajeshBollam #clinicaltrials #kidneycancer #immunotherapy

Add a comment